Loading
IT
IntelGenx Technologies Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Zerbe Horst G, was filed 03 Oct 2022.
IntelGenx Technologies Corp.: what insiders have been doing
IntelGenx Technologies Corp. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of IntelGenx Technologies Corp. in twelve months, the latest record being from 19 April 2023.
Looking back to 2006, when coverage begins, insiders filed 102 purchases and 25 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
171
Thresholds
n/a
Buy Volume
€987,137
102 ops. · all time
Sell Volume
€494,660
25 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$894.6k
Net income-US$8.5M-955.4% margin
Last declaration on 19 April 2023
Declarations171 total
Common SharesTSXSEDI:4117795
14,000 shares@ US$0.12473.1% of flowCommon Stock, 0.00001 p.VSEC:0001062993-22-020119:1
Canonical exit: 29 Dec 2022 (T+90)
5,000 shares@ US$0.128100.0% of flowCommon Stock, 0.00001 p.VSEC:0001062993-22-020119:0
Canonical exit: 29 Dec 2022 (T+90)
5,000 shares@ US$0.1243.3% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-020113:0
Canonical exit: 28 Dec 2022 (T+90)
9,000 shares@ US$0.1351.4% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-020022:1
Canonical exit: 27 Dec 2022 (T+90)
1,000 shares@ US$0.1310.7% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-020022:0
Canonical exit: 26 Dec 2022 (T+90)
9,000 shares@ CA$0.185Common SharesTSXSEDI:4008315
Canonical exit: 27 Dec 2022 (T+90)
1,000 shares@ CA$0.18Common SharesTSXSEDI:4008314
Canonical exit: 26 Dec 2022 (T+90)
19,000 shares@ US$0.13543.5% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-019976:0
Canonical exit: 25 Dec 2022 (T+90)
19,000 shares@ CA$0.185Common SharesTSXSEDI:4007690
Canonical exit: 25 Dec 2022 (T+90)
2,000 shares@ US$0.1482.0% of flowCommon Stock, 0.00001 p.VSEC:0001062993-22-019908:1
Canonical exit: 21 Dec 2022 (T+90)
8,000 shares@ US$0.1477.9% of flowCommon Stock, 0.00001 p.VSEC:0001062993-22-019908:2
Canonical exit: 22 Dec 2022 (T+90)
23,500 shares@ US$0.14556.5% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-019908:0
Canonical exit: 21 Dec 2022 (T+90)
25,000 shares@ CA$0.185Common SharesTSXSEDI:4005997
Canonical exit: 20 Dec 2022 (T+90)
20,000 shares@ CA$0.18Common SharesTSXSEDI:4005993
Canonical exit: 20 Dec 2022 (T+90)
25,000 shares@ US$0.13826.2% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-019838:0
Canonical exit: 20 Dec 2022 (T+90)
20,000 shares@ US$0.13414.4% of flowCommon Stock, 0.00001 p.VSEC:0001062993-22-019862:0
Canonical exit: 20 Dec 2022 (T+90)
10,526 shares@ US$0.2963.5% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-016168:1
2,105 shares@ US$0.2960.7% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-016170:1
71,123 shares@ US$0.2281.5% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-016170:0
355,618 shares@ US$0.22100.0% of flowCommon Stock, 0.00001 p.V.SEC:0001062993-22-016168:0
10,526 shares@ CA$0.38Common SharesTSXSEDI:3975995
2,105 shares@ CA$0.38Common SharesTSXSEDI:3976000
355,618 shares@ CA$0.2812Common SharesTSXSEDI:3975992
71,123 shares@ CA$0.2812Common SharesTSXSEDI:3975999
25 of 171 declarations
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp. is a specialty pharmaceutical and drug-delivery company listed in the United States on the NASDAQ market. Although it is followed by U.S. investors and trades as a U.S.-listed equity, the company’s operating roots are Canadian: it was founded in 2003, later reorganized in 2006, and is headquartered in Montreal, Quebec, Canada. That dual profile matters for investors, because IntelGenx is a small-cap biotech/pharma name whose valuation is driven less by scale and more by intellectual property, development milestones, partner traction, and manufacturing execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
The company’s core activity is the development and contract manufacturing of novel oral drug-delivery products, especially oral thin films designed for rapid dissolution or controlled release. In practice, IntelGenx operates as a specialized CDMO-like platform: it offers pharmaceutical R&D, regulatory support, technology transfer, manufacturing scale-up, and commercial production services to partners. This business model can create multiple monetization paths—service fees, manufacturing revenues, and potentially royalties—if a program progresses successfully through development and into launch. Its proprietary technology set includes VersaFilm™, DisinteQ™, and VetaFilm™, with the latter aimed at veterinary applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, IntelGenx occupies a niche position. It is not a large-cap pharmaceutical manufacturer; rather, it competes as a technology-driven formulation specialist. Its edge depends on proving that its oral-film and related delivery platforms can offer practical patient benefits, scalable manufacturing, and attractive partner economics. For investors, that means the company should be assessed as a platform business: success is tied to licensing, partnering, and the commercialization of programs, not to a broad commercial drug portfolio. The company has also explored adjacent markets such as non-prescription cannabis-infused oral films in Canada and psychedelic-related opportunities through strategic partnerships, showing an effort to broaden the applicability of its delivery expertise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
Geographically, IntelGenx is Canadian in operations but U.S.-oriented in market visibility because of its NASDAQ listing in the United States. That mix is common among development-stage healthcare companies seeking access to deeper U.S. capital markets while retaining a Canadian operating base. The company’s headquarters in Montreal also anchors its manufacturing and development footprint, which is relevant when evaluating operating costs, regulatory oversight, and cross-border execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
Recent developments point to a company still in transition. SEC filings and related disclosures reference loan amendments, strategic financing arrangements, and ongoing relationships involving atai Life Sciences. The record also reflects restructuring-related activity around IntelGenx’s operating assets in 2024–2025, underscoring that the story is as much about balance-sheet management as it is about technology development. In short, IntelGenx remains a high-risk, high-optional-value specialty pharma platform: attractive for investors who understand early-stage execution risk, but still dependent on funding, partnerships, and successful commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299324006905/form10k.htm?utm_source=openai))
